Drugs / ADOMEGLIVANT
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials · 1 missed | ||||||
| Phase 1 | NCT02385084 | Mar → May 2015 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT02217618 | Aug → Sep 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01929109 | Aug 2013 → Aug 2014 | chronic renal failure syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01836198 | May → Nov 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01640834 | Jul → Sep 2012 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | Missed primary |
| Phase 1 | NCT01588366 | Apr 2012 → Sep 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01460368 | Oct 2011 → Mar 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01354496 | Apr → Oct 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01606397 | Mar → Nov 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01606423 | Nov 2007 → Mar 2008 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01606371 | May → Oct 2007 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 24 trials · 2 met primary | ||||||
| Phase 2 | NCT02111096 | Apr 2014 → Sep 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT02091362 | Mar 2014 → Jan 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01241448 | Jan 2011 → Feb 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT00871572 | Mar 2009 → Feb 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| — | NCT02944110 Comparator | Apr 2016 → Nov 2019 | post-surgical hypoinsulinemia | University Hospital, Gentofte, Copenhagen | Unknown | No outcome recorded |
| — | NCT02669524 Comparator | Oct 2015 → Aug 2016 | type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADOMEGLIVANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707351 ↗ |
| Known as | LY2409021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02669524 ↗ |
| Action | Inhibit | “glucagon receptor antagonist” PMID 26681715 ↗ Dec 20151“Glucagon receptor antagonist” CHEMBL3707351 ↗ |
| Modality | Small molecule | “a potent, selective small-molecule glucagon receptor antagonist” PMID 26681715 ↗ Dec 2015 |
| Route | Oral | “once-daily oral administration of LY2409021” PMID 26681715 ↗ Dec 2015 |
| Target | GCGR | “Glucagon receptor antagonist” CHEMBL3707351 ↗ |